Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating & Analysis

Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics. RNAi is a naturally occurring cellular pathway for sequence-specific silencing and regulation of gene expression. Its commercial RNAi products, all developed and commercialized by Alnylam, include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1).